Literature DB >> 35867756

An immature, dedifferentiated, and lineage-deconstrained cone precursor origin of N-Myc-initiated retinoblastoma.

Hardeep P Singh1,2,3, Dominic W H Shayler1,2, G Esteban Fernandez2, Matthew E Thornton4, Cheryl Mae Craft3,5, Brendan H Grubbs4, David Cobrinik1,2,3,6,7.   

Abstract

Most retinoblastomas develop from maturing cone precursors in response to biallelic RB1 loss and are dependent on cone maturation-related signaling. Additionally, ∼2% lack RB1 mutations but have MYCN amplification (MYCNA), N-Myc protein overexpression, and more rapid and invasive growth, yet the MYCNA retinoblastoma cell of origin and basis for its responses to deregulated N-Myc are unknown. Here, using explanted cultured retinae, we show that ectopic N-Myc induces cell cycle entry in cells expressing markers of several retinal types yet induces continuous proliferation and tumorigenesis only in cone precursors. Unlike the response to RB1 loss, both immature cone arrestin-negative (ARR3-) and maturing ARR3+ cone precursors proliferate, and maturing cone precursors rapidly dedifferentiate, losing ARR3 as well as L/M-opsin expression. N-Myc-overexpressing retinal cells also lose cell lineage constraints, occasionally coexpressing the cone-specific RXRγ with the rod-specific NRL or amacrine-specific AP2α and widely coexpressing RXRγ with the progenitor and Müller cell-specific SOX9 and retinal ganglion cell-specific BRN3 and GAP43. Mechanistically, N-Myc induced Cyclin D2 and CDK4 overexpression, pRB phosphorylation, and SOX9-dependent proliferation without a retinoma-like stage that characterizes pRB-deficient retinoblastoma, despite continuous p16INK4A expression. Orthotopic xenografts of N-Myc-overexpressing retinal cells formed tumors with retinal cell marker expression similar to those in MYCN-transduced retinae and MYCNA retinoblastomas in patients. These findings demonstrate the MYCNA retinoblastoma origin from immature and lineage-deconstrained cone precursors, reveal their opportunistic use of an undifferentiated retinal progenitor cell feature, and illustrate that different cancer-initiating mutations cooperate with distinct developmental stage-specific cell signaling circuitries to drive retinoblastoma tumorigenesis.

Entities:  

Keywords:  MYCN; cancer cell of origin; cone precursor; dedifferentiation; retinoblastoma

Mesh:

Substances:

Year:  2022        PMID: 35867756      PMCID: PMC9282279          DOI: 10.1073/pnas.2200721119

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   12.779


  41 in total

1.  Distinct neural stem cell populations give rise to disparate brain tumors in response to N-MYC.

Authors:  Fredrik J Swartling; Vasil Savov; Anders I Persson; Justin Chen; Christopher S Hackett; Paul A Northcott; Matthew R Grimmer; Jasmine Lau; Louis Chesler; Arie Perry; Joanna J Phillips; Michael D Taylor; William A Weiss
Journal:  Cancer Cell       Date:  2012-05-15       Impact factor: 31.743

2.  Direct induction of cyclin D2 by Myc contributes to cell cycle progression and sequestration of p27.

Authors:  C Bouchard; K Thieke; A Maier; R Saffrich; J Hanley-Hyde; W Ansorge; S Reed; P Sicinski; J Bartek; M Eilers
Journal:  EMBO J       Date:  1999-10-01       Impact factor: 11.598

3.  Cross-Cohort Analysis Identifies a TEAD4-MYCN Positive Feedback Loop as the Core Regulatory Element of High-Risk Neuroblastoma.

Authors:  Presha Rajbhandari; Gonzalo Lopez; Claudia Capdevila; Beatrice Salvatori; Jiyang Yu; Ruth Rodriguez-Barrueco; Daniel Martinez; Mark Yarmarkovich; Nina Weichert-Leahey; Brian J Abraham; Mariano J Alvarez; Archana Iyer; Jo Lynne Harenza; Derek Oldridge; Katleen De Preter; Jan Koster; Shahab Asgharzadeh; Robert C Seeger; Jun S Wei; Javed Khan; Jo Vandesompele; Pieter Mestdagh; Rogier Versteeg; A Thomas Look; Richard A Young; Antonio Iavarone; Anna Lasorella; Jose M Silva; John M Maris; Andrea Califano
Journal:  Cancer Discov       Date:  2018-03-06       Impact factor: 39.397

Review 4.  Tissue, cell and stage specificity of (epi)mutations in cancers.

Authors:  Oliver M Sieber; Simon R Tomlinson; Ian P M Tomlinson
Journal:  Nat Rev Cancer       Date:  2005-08       Impact factor: 60.716

5.  The p53 regulatory gene MDM2 is a direct transcriptional target of MYCN in neuroblastoma.

Authors:  Andrew Slack; Zaowen Chen; Roberto Tonelli; Martin Pule; Lisa Hunt; Andrea Pession; Jason M Shohet
Journal:  Proc Natl Acad Sci U S A       Date:  2005-01-11       Impact factor: 11.205

Review 6.  Tissue-specific tumorigenesis: context matters.

Authors:  Günter Schneider; Marc Schmidt-Supprian; Roland Rad; Dieter Saur
Journal:  Nat Rev Cancer       Date:  2017-03-03       Impact factor: 60.716

7.  MYC-driven epigenetic reprogramming favors the onset of tumorigenesis by inducing a stem cell-like state.

Authors:  Vittoria Poli; Luca Fagnocchi; Alessandra Fasciani; Alessandro Cherubini; Stefania Mazzoleni; Sara Ferrillo; Annarita Miluzio; Gabriella Gaudioso; Valentina Vaira; Alice Turdo; Miriam Gaggianesi; Aurora Chinnici; Elisa Lipari; Silvio Bicciato; Silvano Bosari; Matilde Todaro; Alessio Zippo
Journal:  Nat Commun       Date:  2018-03-09       Impact factor: 14.919

8.  Human embryonic stem cell-derived organoid retinoblastoma reveals a cancerous origin.

Authors:  Hui Liu; Yan Zhang; You-You Zhang; Yan-Ping Li; Zi-Qi Hua; Chang-Jun Zhang; Kun-Chao Wu; Fulong Yu; Yaru Zhang; Jianzhong Su; Zi-Bing Jin
Journal:  Proc Natl Acad Sci U S A       Date:  2020-12-14       Impact factor: 11.205

9.  Somatic genomic alterations in retinoblastoma beyond RB1 are rare and limited to copy number changes.

Authors:  Irsan E Kooi; Berber M Mol; Maarten P G Massink; Najim Ameziane; Hanne Meijers-Heijboer; Charlotte J Dommering; Saskia E van Mil; Yne de Vries; Annemarie H van der Hout; Gertjan J L Kaspers; Annette C Moll; Hein Te Riele; Jacqueline Cloos; Josephine C Dorsman
Journal:  Sci Rep       Date:  2016-04-29       Impact factor: 4.379

Review 10.  SOX9 Stem-Cell Factor: Clinical and Functional Relevance in Cancer.

Authors:  Maribel Aguilar-Medina; Mariana Avendaño-Félix; Erik Lizárraga-Verdugo; Mercedes Bermúdez; José Geovanni Romero-Quintana; Rosalío Ramos-Payan; Erika Ruíz-García; César López-Camarillo
Journal:  J Oncol       Date:  2019-04-01       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.